Westminster Health Forum policy conference:

Priorities for medicine access, supply and pricing in the UK

Timing: Morning, Tuesday, 23rd April 2024

Taking Place Online

Agenda subject to change

8.30 Registration



9.00 Chair's opening remarks

Rt Hon Lord Hunt of Kings Heath, former Parliamentary Under-Secretary of State for Health (1999 - 2003)

9.05 Examining the landscape for medicine accessibility and affordability in the UK

Elizabeth Hampson, Partner, Deloitte Questions and comments from the floor

9.30 Exploring emerging trends and priorities for improving medicine supply and accessibility

Options for mitigating medicine shortages and supply chain disruption | Building resilience and stability across the supply chain |

Maintaining continuity of patient care and access to medicines | The role of VPAG

Professor Zaheer-Ud-Din Babar, Professor in Medicines and Healthcare, University of Huddersfield

Yousaf Ahmad, ICS Chief Pharmacist and Director of Medicines Optimisation, Frimley Health and Care Integrated Care System Alison Dennis, Partner, Taylor Wessing

Dominic Wake, Head of Corporate Affairs and Market Access, Sandoz UK & Ireland

Bushra Effendi, Pharmacist and Clinical Advisor, The Menopause Charity

Questions and comments from the floor

10.30 Priorities for economic growth in the UK life sciences sector, and coordinating policy to drive investment and innovation

Anusha Foy, Partner, Head of Life Sciences Regulatory Solutions Practice, KPMG

Questions and comments from the floor

10.55 Chair's closing remarks

Rt Hon Lord Hunt of Kings Heath, former Parliamentary Under-Secretary of State for Health (1999 - 2003)

11.00 Break

11.10 Chair's opening remarks

Rt Hon Lord Lansley, former Secretary of State for Health (2010 - 2012)

11.15 <u>Examining opportunities for market access and innovation in the VPAG scheme</u>

David Watson, Executive Director, Patient Access, Association of the British Pharmaceutical Industry **Kim Assender**, Director of Commercial Policy and Analysis, Association of the British Pharmaceutical Industry Questions and comments from the floor

11.40 <u>Assessing the outlook for advanced therapy medicinal products, regulatory pathways and payment models</u>

Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult Questions and comments from the floor

12.05 <u>Next steps for implementation of the VPAG scheme</u>

Transparency and options for monitoring and reporting | patient priorities for the scheme and accessibility to innovative medicine | regulatory pathways | financial sustainability and value for money in the NHS

Dr Scott Purdon, Head of Patient Advocacy, Myeloma UK

Leela Barham, Health Economics Researcher and Writer; and Senior Lecturer, University of South Wales

Jessamy Baird, General Manager, General Medicines, UK & Ireland, Sanofi

Questions and comments from the floor

12.55 <u>Chair's and Westminster Health Forum closing remarks</u>

Rt Hon Lord Lansley, former Secretary of State for Health (2010 - 2012)

Jessica Lear, Westminster Health Forum